High-throughput metabolomics identifies new biomarkers for cervical cancer
Abstract Background Cervical cancer (CC) is a danger to women’s health, especially in many developing countries. Metabolomics can make the connection between genotypes and phenotypes. It provides a wide spectrum profile of biological processes under pathological or physiological conditions. Method I...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-03-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-024-00948-8 |
_version_ | 1797233437060366336 |
---|---|
author | Xue Li Liyi Zhang Xuan Huang Qi Peng Shoutao Zhang Jiangming Tang Jing Wang Dingqing Gui Fanxin Zeng |
author_facet | Xue Li Liyi Zhang Xuan Huang Qi Peng Shoutao Zhang Jiangming Tang Jing Wang Dingqing Gui Fanxin Zeng |
author_sort | Xue Li |
collection | DOAJ |
description | Abstract Background Cervical cancer (CC) is a danger to women’s health, especially in many developing countries. Metabolomics can make the connection between genotypes and phenotypes. It provides a wide spectrum profile of biological processes under pathological or physiological conditions. Method In this study, we conducted plasma metabolomics of healthy volunteers and CC patients and integratively analyzed them with public CC tissue transcriptomics from Gene Expression Omnibus (GEO). Result Here, we screened out a panel of 5 metabolites to precisely distinguish CC patients from healthy volunteers. Furthermore, we utilized multi-omics approaches to explore patients with stage I-IIA1 and IIA2-IV4 CC and comprehensively analyzed the dysregulation of genes and metabolites in CC progression. We identified that plasma levels of trimethylamine N-oxide (TMAO) were associated with tumor size and regarded as a risk factor for CC. Moreover, we demonstrated that TMAO could promote HeLa cell proliferation in vitro. In this study, we delineated metabolic profiling in healthy volunteers and CC patients and revealed that TMAO was a potential biomarker to discriminate between I-IIA1 and IIA2-IV patients to indicate CC deterioration. Conclusion Our study identified a diagnostic model consisting of five metabolites in plasma that can effectively distinguish CC from healthy volunteers. Furthermore, we proposed that TMAO was associated with CC progression and might serve as a potential non-invasive biomarker to predict CC substage. Impact These findings provided evidence of the important role of metabolic molecules in the progression of cervical cancer disease, as well as their ability as potential biomarkers. |
first_indexed | 2024-04-24T16:16:09Z |
format | Article |
id | doaj.art-0e372e5cf1a2452eae184ba5e61ffd28 |
institution | Directory Open Access Journal |
issn | 2730-6011 |
language | English |
last_indexed | 2024-04-24T16:16:09Z |
publishDate | 2024-03-01 |
publisher | Springer |
record_format | Article |
series | Discover Oncology |
spelling | doaj.art-0e372e5cf1a2452eae184ba5e61ffd282024-03-31T11:24:16ZengSpringerDiscover Oncology2730-60112024-03-0115111110.1007/s12672-024-00948-8High-throughput metabolomics identifies new biomarkers for cervical cancerXue Li0Liyi Zhang1Xuan Huang2Qi Peng3Shoutao Zhang4Jiangming Tang5Jing Wang6Dingqing Gui7Fanxin Zeng8Department of Clinical Research Center, Dazhou Central HospitalDepartment of Gynaecology and Obstetrics, Dazhou Central HospitalDepartment of Medical Research Center, Beijing Chaoyang Hospital, Capital Medical UniversityDepartment of Gynaecology and Obstetrics, Dazhou Central HospitalDepartment of Gynaecology and Obstetrics, Dazhou Central HospitalDepartment of Gynaecology and Obstetrics, Dazhou Central HospitalDepartment of Clinical Laboratory, Beijing Anding Hospital, Capital Medical UniversityDepartment of Gynaecology and Obstetrics, Dazhou Central HospitalDepartment of Clinical Research Center, Dazhou Central HospitalAbstract Background Cervical cancer (CC) is a danger to women’s health, especially in many developing countries. Metabolomics can make the connection between genotypes and phenotypes. It provides a wide spectrum profile of biological processes under pathological or physiological conditions. Method In this study, we conducted plasma metabolomics of healthy volunteers and CC patients and integratively analyzed them with public CC tissue transcriptomics from Gene Expression Omnibus (GEO). Result Here, we screened out a panel of 5 metabolites to precisely distinguish CC patients from healthy volunteers. Furthermore, we utilized multi-omics approaches to explore patients with stage I-IIA1 and IIA2-IV4 CC and comprehensively analyzed the dysregulation of genes and metabolites in CC progression. We identified that plasma levels of trimethylamine N-oxide (TMAO) were associated with tumor size and regarded as a risk factor for CC. Moreover, we demonstrated that TMAO could promote HeLa cell proliferation in vitro. In this study, we delineated metabolic profiling in healthy volunteers and CC patients and revealed that TMAO was a potential biomarker to discriminate between I-IIA1 and IIA2-IV patients to indicate CC deterioration. Conclusion Our study identified a diagnostic model consisting of five metabolites in plasma that can effectively distinguish CC from healthy volunteers. Furthermore, we proposed that TMAO was associated with CC progression and might serve as a potential non-invasive biomarker to predict CC substage. Impact These findings provided evidence of the important role of metabolic molecules in the progression of cervical cancer disease, as well as their ability as potential biomarkers.https://doi.org/10.1007/s12672-024-00948-8Cervical cancerMetabolitesTrimethylamine N-oxidePrognosis |
spellingShingle | Xue Li Liyi Zhang Xuan Huang Qi Peng Shoutao Zhang Jiangming Tang Jing Wang Dingqing Gui Fanxin Zeng High-throughput metabolomics identifies new biomarkers for cervical cancer Discover Oncology Cervical cancer Metabolites Trimethylamine N-oxide Prognosis |
title | High-throughput metabolomics identifies new biomarkers for cervical cancer |
title_full | High-throughput metabolomics identifies new biomarkers for cervical cancer |
title_fullStr | High-throughput metabolomics identifies new biomarkers for cervical cancer |
title_full_unstemmed | High-throughput metabolomics identifies new biomarkers for cervical cancer |
title_short | High-throughput metabolomics identifies new biomarkers for cervical cancer |
title_sort | high throughput metabolomics identifies new biomarkers for cervical cancer |
topic | Cervical cancer Metabolites Trimethylamine N-oxide Prognosis |
url | https://doi.org/10.1007/s12672-024-00948-8 |
work_keys_str_mv | AT xueli highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT liyizhang highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT xuanhuang highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT qipeng highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT shoutaozhang highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT jiangmingtang highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT jingwang highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT dingqinggui highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer AT fanxinzeng highthroughputmetabolomicsidentifiesnewbiomarkersforcervicalcancer |